Voglibose is used in the treatment of diabetes mellitus (DM) to reduce Post-Prandial Hyperglycemia (PPHG), but only when diet and/or exercise, along with lifestyle changes or oral hypoglycemic agents (OHAs) or insulin preparations, do not result in adequate glycemic control.

Pharmaceutical Name

Pharmacology

When compared to blood, the lens has a high concentration of vitamin C. Long-term use of Vitamin C supplements (10+ years) has been linked to a lower risk of cataracts. Vitamin C plays a crucial function in the scavenging of damaging free radicals.

High serum Vitamin E concentrations have been linked to a lower incidence of cataracts, according to a study (exact mechanism of action is not still established). It also plays a crucial role in the scavenging of damaging free radicals as an antioxidant vitamin.

Lutein is a carotenoid that is found in high concentration in the macula. This caretenoid may protect the macula from oxidative or light damage, according to clinical and animal research.

Although the actual mechanism of action is unknown, one big study indicated that high dietary Lutein levels are linked to a decreased incidence of AMD (Age-Related Macular Degeneration). Zinc is a trace element that is involved in several enzyme systems.

Taste, smell, and wound healing are all altered or missing in people with a less severe impairment. Skin lesions, baldness, diarrhea, increased susceptibility to infection, and failure to thrive are all symptoms of severe insufficiency in children.

Copper is necessary for growth, bone integrity, and nervous system development. It participates in multiple metabolic transformations as a component of different enzymes.

Dosage & Administration of Vibose 0.3

Normal Adult Dose: Usually, Voglibose tablets are orally administered in a single dose of 0.2 mg, 3 times a day, before each meal. If the effect is not sufficient, the quantity of a single dose may be increased up to 0.3 mg.

Pediatrics: The safety and effectiveness of Voglibose in children has not been established.

Geriatrics: Since elderly patients generally have a physiological hypofunction, it is desirable that such caution be taken as starting the administration at a lower dose (eg, 0.1 mg at a time). Furthermore, this drug should be carefully administered under close observation, through the course of the disease condition, with careful attention to the blood sugar level and the onset of gastrointestinal symptoms.

Interaction of Vibose 0.3

When used with the following medications, Voglibose should be used with caution:

Anti-diabetic medications include sulfonylamide and sulfonylurea derivatives, biguanide derivatives, insulin preparations, and insulin resistance improving agents.

When antldlabetlc medications and drugs that promote or lessen the hypoglycaemic activity of antldlabetlc drugs are taken together, the following precautions should be taken:

• Blockers, salicylic acid preparations, monoamine oxidase inhibitors, fibrate derivatives for hyperlipemia therapy, warfarin, and other medications that enhance the hypoglycaemic action of antidiabetic drugs
• Adrenaline, adrenocortical hormone, thyroid hormone, and other medicines that reduce the hypoglycemic effect of anti-diabetic drugs

Contraindications

Patients with hypersensitivity to Voglibose or any of the excipients should not take this medication. Diabetic ketoacidosis and diabetic pre-coma are both symptoms of diabetic ketoacidosis. Severe infection, both before and after surgery, or as a result of serious trauma; Obstruction of the gastrointestinal tract or a predisposition to it.

Side Effects of Vibose 0.3

Diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, nausea, vomiting, heartburn, increased gas, and intestinal obstruction-like symptoms due to increased intestinal gas are all symptoms of increased intestinal gas. Hypoglycemia (0.1 percent to 5%) and a delay in disaccharide digestion and absorption may occur when OHAs are combined with voglibose.

Pregnancy & Lactation

Pregnancy: The safety of Voglibose during pregnancy has yet to be determined. However, no adequate and well-controlled studies on pregnant women have been conducted.

Lactating and nursing mothers: Despite the fact that the levels of Voglibose found in human milk are extremely low, it is not recommended that Voglibose be given to these women.

Precautions & Warnings

Careful Administration (should be given with caution to subsequent patients):

• Patients taking other anti-diabetic medications, as hypoglycemia can ensue.
• Patients who have had a laparotomy or have had an ileus (intestinal obstruction-like symptoms are liable to develop due to an increase in intestinal gas, etc.)
• Patients with chronic intestinal illness who have difficulty digesting and absorbing food (the action of this drug may aggravate the pathologic conditions)
• Patients with Roemheld’s Syndrome, severe hernias, large intestine stenosis or ulceration, and so on. (Symptoms may intensify as a result of an increase in intestinal gas, for example.)
• Patients with severe hepatic impairment (The state of plasma glucose control may substantially fluctuate due to possible variations in metabolic condition.) Hyperammonemia may worsen in patients with severe liver cirrhosis, leading to a loss of consciousness.)
• Patients with severe renal failure (The state of plasma glucose management may substantially fluctuate according to possible changes in metabolic circumstances.)
• Patients who are elderly

Therapeutic Class

Inhibitor of alpha-glucosidase

Storage Conditions

Keep the temperature below and away from light and moisture. Keep out of children’s reach.